Literature DB >> 8080997

Primary leukemia cells resistant to alpha-interferon in vitro are defective in the activation of the DNA-binding factor interferon-stimulated gene factor 3.

B Xu1, D Grandér, O Sangfelt, S Einhorn.   

Abstract

Cells from one-third of chronic lymphocytic leukemia (CLL) patients are resistant to alpha-interferon (alpha-IFN) as measured by induction of blast transformation. We have previously shown that all CLL clones express alpha/beta-IFN receptors, but that the resistant cells are defective in the induction of the enzyme 2',5'-oligoadenylate synthetase (2',5-A synthetase). Thus, the deficiency in IFN sensitivity is localized somewhere between the interaction of the IFN molecule with its receptor and induction of 2',5'-A synthetase. We have now further characterized the resistance of CLL clones to IFN by investigating whether it is associated with a defect in the activation of IFN-stimulated gene factor 3 (ISGF3), which is involved in the activation of alpha-IFN-stimulated genes (ISGs). A defect induction of ISGF3 after alpha-IFN treatment was found in 4 of 12 CLL patients. There was a close correlation between defective induction of ISGF3 and a lack of enhancement of 2',5'-A synthetase as well as induction of blast transformation. Pretreatment with gamma-IFN and mixing experiments with extracts from IFN-sensitive cells indicate that a lack of the gamma-component of ISGF3 was the reason for defect in activation in 2 of the patients. We conclude that a defect in activation of ISGF3 is a possible cause for resistance in CLL cells to IFN-induced blast transformation in vitro.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080997

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors.

Authors:  Diana L Thomas; Rosalinda Doty; Vesna Tosic; Jia Liu; David M Kranz; Grant McFadden; Amy L Macneill; Edward J Roy
Journal:  Cancer Immunol Immunother       Date:  2011-06-09       Impact factor: 6.968

2.  Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.

Authors:  Sateesh Krishnamurthy; Toru Takimoto; Ruth Ann Scroggs; Allen Portner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma.

Authors:  Juan Carlos Ramos; Phillip Ruiz; Lee Ratner; Isildinha M Reis; Carlos Brites; Celia Pedroso; Gerald E Byrne; Ngoc L Toomey; Valentine Andela; Edward W Harhaj; Izidore S Lossos; William J Harrington
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 4.  Apoptosis and cell growth inhibition as antitumor effector functions of interferons.

Authors:  H Strander
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

5.  Mechanisms of resistance to interferon-gamma-mediated cell growth arrest in human oral squamous carcinoma cells.

Authors:  Miki Hiroi; Kazumasa Mori; Keisuke Sekine; Yoshiichi Sakaeda; Jun Shimada; Yoshihiro Ohmori
Journal:  J Biol Chem       Date:  2009-07-13       Impact factor: 5.157

6.  A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon.

Authors:  Maria D Gainey; Mary J Manuse; Griffith D Parks
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

7.  Interferon-resistant Daudi cell line with a Stat2 defect is resistant to apoptosis induced by chemotherapeutic agents.

Authors:  Ziyun Du; Meiyun Fan; Jong-Gwan Kim; Dara Eckerle; Leonard Lothstein; Lai Wei; Lawrence M Pfeffer
Journal:  J Biol Chem       Date:  2009-08-17       Impact factor: 5.157

8.  Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for Oncolytic Virus Therapy.

Authors:  Candace R Fox; Griffith D Parks
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

9.  Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.

Authors:  Heather MacTavish; Jean-Simon Diallo; Baocheng Huang; Marianne Stanford; Fabrice Le Boeuf; Naomi De Silva; Julie Cox; John Graydon Simmons; Tanya Guimond; Theresa Falls; J Andrea McCart; Harry Atkins; Caroline Breitbach; David Kirn; Stephen Thorne; John C Bell
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

10.  Enhancement of sensitivity of human lung adenocarcinoma cells to growth-inhibitory activity of interferon alpha by differentiation-inducing agents.

Authors:  I Goto; Y Yamamoto-Yamaguchi; Y Honma
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.